Efficacy of VTP-300 in Chronic Hepatitis B Infection
Market
0.0%
Details
- Resolved Date
- 11/15/24
- Study Completion
- 10/1/26
- Company
- Barinthus Biotherapeutics
- Ticker
- BRNS
- Type
- Trial Status
- Active Not Recruiting
- Trial Size
- 120
- Volume
- $0
- NCT
- NCT05343481
- Drug Description
- This is an open-label study to determine the efficacy, safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV, together VTP-300, in combination with low-dose nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Exact trial NCT05343481 had a trial-specific public interim readout framed positively: Barinthus reported HBsAg loss in 8 participants, 2 functional cures, and said the Phase 2 data were “incredibly encouraging.” Independent conference coverage also described the regimen as showing potential for HBV cure.
Sources
Sponsorinvestors.barinthusbio.com11/15/24
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
For HBV003/NCT05343481, Barinthus reported 8 participants with HBsAg loss, 2 meeting functional cure criteria, generally good tolerability, and called the Phase 2 data “incredibly encouraging.”
View source
Web Searchhcplive.com11/12/23
VTP-300 Plus Nivolumab Lowers HBsAG, Shows Potential for HBV Cure Regimen
Coverage of the ongoing HBV003 Phase 2b trial said interim data showed HBsAg reductions and highlighted a potential role for VTP-300 plus nivolumab in functionally curing HBV.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
